The kit, developed by BGI Patho-Genesis Pharmaceutical Technology, is designed to construct a metagenomic sequencing library directly from clinical samples.
Both RT-PCR tests are for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B from throat swab samples.
BGI will have a chance to depose up to nine inventors of patents assigned to Illumina as part of a lawsuit over IP related to sequencing-by-synthesis chemistry.
The US Commerce Department has placed two BGI Group subsidiaries on a list of entities it suspects of human rights violations, allegations the company denies, Reuters reports.
